1. Home
  2. ADPT vs BCC Comparison

ADPT vs BCC Comparison

Compare ADPT & BCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADPT
  • BCC
  • Stock Information
  • Founded
  • ADPT 2009
  • BCC 2004
  • Country
  • ADPT United States
  • BCC United States
  • Employees
  • ADPT N/A
  • BCC N/A
  • Industry
  • ADPT Biotechnology: Biological Products (No Diagnostic Substances)
  • BCC RETAIL: Building Materials
  • Sector
  • ADPT Health Care
  • BCC Consumer Discretionary
  • Exchange
  • ADPT Nasdaq
  • BCC Nasdaq
  • Market Cap
  • ADPT 2.6B
  • BCC 2.6B
  • IPO Year
  • ADPT 2019
  • BCC 2013
  • Fundamental
  • Price
  • ADPT $20.36
  • BCC $75.40
  • Analyst Decision
  • ADPT Strong Buy
  • BCC Strong Buy
  • Analyst Count
  • ADPT 10
  • BCC 7
  • Target Price
  • ADPT $16.60
  • BCC $102.50
  • AVG Volume (30 Days)
  • ADPT 2.4M
  • BCC 502.5K
  • Earning Date
  • ADPT 11-05-2025
  • BCC 11-03-2025
  • Dividend Yield
  • ADPT N/A
  • BCC 1.18%
  • EPS Growth
  • ADPT N/A
  • BCC N/A
  • EPS
  • ADPT N/A
  • BCC 5.07
  • Revenue
  • ADPT $252,754,000.00
  • BCC $6,511,894,000.00
  • Revenue This Year
  • ADPT $36.43
  • BCC N/A
  • Revenue Next Year
  • ADPT $12.31
  • BCC $3.58
  • P/E Ratio
  • ADPT N/A
  • BCC $14.68
  • Revenue Growth
  • ADPT 42.57
  • BCC N/A
  • 52 Week Low
  • ADPT $4.76
  • BCC $65.14
  • 52 Week High
  • ADPT $20.76
  • BCC $155.42
  • Technical
  • Relative Strength Index (RSI)
  • ADPT 73.37
  • BCC 61.27
  • Support Level
  • ADPT $13.28
  • BCC $65.14
  • Resistance Level
  • ADPT $14.24
  • BCC $73.22
  • Average True Range (ATR)
  • ADPT 1.19
  • BCC 2.21
  • MACD
  • ADPT 0.57
  • BCC 0.81
  • Stochastic Oscillator
  • ADPT 95.19
  • BCC 97.98

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

About BCC Boise Cascade L.L.C.

Boise Cascade Co is a producer of engineered wood products (EWP) and plywood. The firm operates in two reportable segments, namely Wood Products and Building Materials Distribution. The Wood Products segment manufactures laminated veneer lumber (LVL), I-joists, and laminated beams. In addition, it manufactures structural, appearance, and industrial-grade plywood panels, and ponderosa pine lumber. The Building Materials Distribution segment is engaged in the distribution of various building materials, including oriented strand board (OSB), plywood, and lumber; general line items such as siding, composite decking, doors and millwork, metal products, roofing, and insulation; and EWP, among others. The company generates a majority of its revenue from the Building Material Distribution segment.

Share on Social Networks: